Kornimate/medical-research-clean huggingface dataset:
[s,s]-reboxetine add-on trial

Conditions: Pain

Summary: the purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with \[s,s\]-reboxetine against pregabalin monotherapy in patients with phn


Eligibility criteria:
inclusion criteria: * patients must have pain present for more than 3 months after the healing of shingles skin rash * patients at screening must have a score \>/=40 mm on the pain visual analogue scale exclusion criteria: * patients with significant renal and hepatic impairment * patients with other severe pain, that may impair the self-assessment of the pain due to shingles * patients with clinically abnormal electrocardiogram
experience of pain during oocyte retrieval- a comparison between two aspiration needles

Conditions: Infertility

Summary: the purpose of the study is to compare the pain experience between the patients that have had their transvaginal oocytes retrieval with ultrasound guidance performed with reduced single lumen needle (vitrolife sweden ab, gothenburg) with the patients that have had follicle aspiration needle, 1.4 outer diameter (vitrolife sweden ab, gothenburg), during the procedure.

although the patient is sedated and local analgesia has been given, transvaginal oocytes retrieval with ultrasound guidance can still cause a lot of pain, both during and after the procedure. to reduce the pain, some clinics prefer to use needles as thin as 0.8 mm (outer diameter, od). a disadvantage with these needles is the increased aspiration time. therefore a new needle has been developed that has the possibility to reduce pain without a large increase in aspiration time. the needle has a 50 mm long tip with an outer diameter of 0.9 mm. the remaining part of the needle is 300 mm long with an outer diameter of 1.4 mm.

Eligibility criteria:
inclusion criteria: * the patient has signed an informed consent form before the oocyte retrieval * the patient is undergoing oocyte retrieval with local anaesthesia * the patient can speak and understand swedish exclusion criteria: * the patient has previously participated in vitrolife-needle-01 study * the patient has a body mass index ≥35 * other contra indicator for oocyte retrieval

Keywords: reproductive medicine fertilization in vitro oocyte retrieval local anaesthesia aspiration needle
impact of bone mineral density on fracture risk assessment in ra

Conditions: Rheumatoid Arthritis

Summary: this study investigates whether incorporating bone mineral density (bmd) into frax calculations changes fracture risk assessment and influences treatment decisions in rheumatoid arthritis (ra) patients. analyzing 60 ra patients, frax scores for 10-year major osteoporotic and hip fractures were calculated with and without bmd. while no significant differences were found between the two methods, discrepancies in treatment recommendations were identified, particularly for hip fractures. the findings emphasize the importance of combining bmd and frax for a more comprehensive fracture risk assessment and informed treatment decision-making in ra patients.


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis (ra) based on acr/eular criteria. * age between 40-90 years. * dual-energy x-ray absorptiometry (dxa) results obtained within the past six months. * availability of complete clinical and demographic data for fracture risk assessment. * patients who provide informed consent for the study. exclusion criteria: * patients with secondary causes of osteoporosis (e.g., hyperparathyroidism, cushing's syndrome). * use of medications affecting bone metabolism (e.g., glucocorticoids \>7.5 mg/day, bisphosphonates, denosumab) within the past year. * history of metabolic bone diseases other than osteoporosis (e.g., osteomalacia, paget's disease). * patients with a history of malignancy, except for non-melanoma skin cancer. * incomplete or missing data required for frax or dxa analysis. * any condition or comorbidity likely to affect fracture risk assessment, as determined by the clinician.
the effects of bed exercises on anxiety, pain, early ambulation and mobilization in patients undergoing major surgery

Conditions: Surgery; Anxiety; Pain

Summary: in this study, the effects of bed exercises on pain, anxiety, early ambulation and mobilization in major surgery patients were aimed. the research was experimental and a total of 120 patients participated. data were collected using an information form, anxiety scale, and pain scale. exercise was applied to the patients in the experimental group (15 minutes) and no intervention was applied to the control group. descriptive statistics, correlation tests and t-test were used. cronbach's alpha coefficients were checked for the scales.

major surgery are operations that can cause morbidity and mortality. worldwide, approximately 230 million major surgical interventions are performed each year. major surgery is a stressful experience and causes life-threatening fear and anxiety by increasing the level of anxiety. the most important of these fears is the pain that may occur after surgery. more than 75% of patients who experience postoperative pain in the western world report that they experience moderate to severe pain. in our country, this rate is over 90%. if pain management is inadequate, patients' quality of life is adversely affected. in pain management, nurses can use non-pharmacological methods such as massage and exercise in addition to pharmacological applications. leg-arm exercises done in bed are aimed at protecting the muscle strength of individuals. turning in bed, leg-arm exercises, raising the heels and feet, inverting the arms, moving from right to left, reverse arm and leg movements are performed. also 6-8. early ambulation is recommended. if these applications are made, early recovery and rapid discharge can be achieved. since pain and anxiety delay early recovery in patients undergoing major surgery, effective pain management is very important. in this study, we aimed to examine the effects of in-bed exercises on anxiety and pain in patients undergoing major surgery.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, * ability to communicate verbally and not having a cognitive problem, * defining pain severity of 4 and above, * willing to participate in the study, * having undergone major surgery. exclusion criteria: * the absence of open wounds and cellulite in the area to be applied, * the absence of thrombophlebitis, * the absence of deep vein thrombosis, * the absence of inflammatory diseases.

Keywords: anxiety early ambulation bed exercise major surgery mobilization
feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia

Conditions: Type 1 Diabetes

Summary: this study will be conducted in a clinical research center (crc) setting and recruiting type 1 diabetes that are currently using an insulin pump.

this study is a non-randomized, uncontrolled feasibility study that looks to enroll people with type 1 diabetes who are currently using an insulin pump. during the subject's participation, the study staff will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.

Eligibility criteria:
inclusion criteria: * age 21-65 years * type 1 diabetes mellitus for at least one year * currently using an insulin infusion pump for at least the past 6 months exclusion criteria: * pregnancy * history of diabetic ketoacidosis (dka) in the past six months * history of severe hypoglycemia (seizure, unconsciousness) in the past 6 months

Keywords: type 1 diabetes insulin pump
intracardiac versus transesophageal echocardiography versus fluoroscopy only guidance for combined catheter ablation for atrial fibrillation and left atrial appendage occlusion

Conditions: Atrial Fibrillation

Summary: a total of 75 patients with atrial fibrillation were scheduled to receive left atrial appendage occlusion combined with radiofrequency ablation, which were divided into 3 groups. the operation was performed under the guidance of intracardiac echocardiography and transesophageal echocardiography and fluoroscope only respectively (allocation ratio 1:1:1). during the operation, the total amount of contrast medium injected, the fluoroscopy time and the time from femoral vein puncture to transseptal puncture to closure were recorded in all patients. all patients underwent transesophageal echocardiography before and 3 months after operation, and the results were explained by two experienced ultrasound doctors to measure the presence of left atrial thrombus, residual shunt and device-related thrombus. all patients were examined by transthoracic echocardiography 3 months after operation to evaluate new pericardial effusion, pericardial tamponade, instrument embolization / displacement and so on. the baseline clinical and surgical features and hospitalization outcomes of patients guided by ice and tee and fluoroscopy only were recorded and compared. clinical endpoints include death, new pericardial effusion that does not require pericardiocentesis, tamponade with pericardiocentesis, instrument embolism / displacement, bleeding at the entry site, thromboembolic events (stroke / transient ischemic attack \[tia\]). the purpose of this study was to evaluate the feasibility, safety and effectiveness of intracardiac echocardiographic (ice)-guided and transesophageal echocardiographic (tee)-guided and fluoroscopy only-guided left atrial appendage occlusion combined with radiofrequency ablation. the average follow-up time is 3 months.


Eligibility criteria:
inclusion criteria: af attack occurred in patients with a duration of more than one year, patients taking class i and class iii antiarrhythmic drugs could not prevent af, patients younger than 80 years old cha2ds2-vasc score ≥2 and has-bled score ≥3, not suitable for long-term oral anticoagulant drugs. exclusion criteria: patients with a history of atrial thrombosis or valvular heart disease (moderate or severe valve stenosis or severe valve regurgitation), patients undergoing prosthetic heart valve replacement, pregnant women, patients with previous liver and kidney diseases, malignant tumors or blood system diseases.
evaluation of prostate-specific antigen (psa) levels in patients with advanced prostate cancer treated with bicalutamide

Conditions: Advanced Prostate Cancer

Summary: prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in croatia. the main aim is to evaluate change of psa level and prescribing practices based on prostate cancer stage.


Eligibility criteria:
inclusion criteria: * patients with diagnosis of advanced prostate cancer * patients who are already treated with bicalutamide for at least 4 weeks and maximum 12 weeks * patients capable of signing icf exclusion criteria: * patients with hypersensitivity to bicalutamide * patients on therapy with terfenadin, astemizol or cisapride * participation in a clinical study during the last 30 days

Keywords: bicalutamide psa advanced prostate cancer
role of pleural fluid attenuation value on ct as a diagnostic tool in traumatic hemothorax

Conditions: Hemothorax; Traumatic

Summary: to define the potential role of pleural fluid attenuation value determined on computed tomography (ct) for diagnosis of traumatic hemothorax and differentiate it from other pleural effusion.

hemothorax is defined as blood accumulation in the pleural space. it is a consequence of blunt trauma in 90% of cases. hemothorax due to blunt trauma mechanisms e.g traffic accidents,sport accidents and falls are among the commonest injuries of the chest. it is manifested in 30-50% of chest trauma cases. in such cases, bleeding might be caused by damage to pulmonary parenchyma or intercostal arteries associated with or without rib fractures and other chest wall tissue injuries including parietal pleura or other thoracic structures. although other pleural effusion types may also manifest such as chylothorax in case of chest trauma, however fluid detected in pleural space is usually considered blood unless proven not to be. despite the clinical and radiological findings provide important data about the content of pleural cavity, however tube thoracostomy and diagnostic thoracocentesis are still required to relieve pressure and characterize the fluid. tube thoracostomy is an invasive procedure which can lead to immediate procedural injuries, infections and pain which can contribute to respiratory failure in patients with chest wall injury. although needle thoracocentesis is less invasive than tube thoracostomy, however it carries small but definitive risks such as pneumothorax, bleeding and chest wall hematoma. since hemothorax is a potentially life threatening, it must be diagnosed quickly and accurately and all these unnecessary complications should be avoided. chest computed tomography \[ct\] has been accepted as the gold standard imaging study for evaluating chest trauma and usually performed in patients with grossly severe chest trauma, as it helps to detect even small hemothorax. ct can also allow for more advanced characterization of pleural fluid and distinguish hemothorax from any other types of effusion by means of scaling hounsfield units as in literature, any attenuation value for pleural fluid between 35 and 70 hu is considered typically blood, so it can be considered as an important non-invasive diagnostic tool for diagnosis of hemothorax in traumatic patients.

Eligibility criteria:
inclusion criteria: * all patients above 18 years old * history of blunt chest trauma * having mild to moderate effusion * ct chest within 1st 24 hours of trauma * patients underwent tube thoracostomy or thoracocentesis exclusion criteria: * patients in need of emergency transfer to surgery. * hemodynamically stable. * patients with penetrating trauma. * patients with no need for tube thoracostomy or thoracocentesis. * patients with minimal effusion. * pregnant females.
negative pressure wound therapy - a multi-centered randomized control trial

Conditions: to See Whether Negative Pressure Wound Therapy Decreases Wound Infections.

Summary: children with neuromuscular disorders such as cerebral palsy, children with kyphosis and post-traumatic scoliosis have higher infection rates after scoliosis surgery than healthy children who undergo scoliosis surgery. the purpose of our study is to compare the effect of npwt on infection rates when compared to standard gauze dressing. participants will be randomized to the "npwt" or "standard dressing" group. we will compare infection rates between the two groups. we hypothesize participants in the "npwt" group will have a lower infection rate.


Eligibility criteria:
inclusion criteria: * male or female * consent/assent to participate in the study * undergoing posterior spinal surgery categorized as high-risk for infection, defined as greater than 4% risk of deep or superficial infection based previous reported literature. procedures qualifying for study are listed below: * kyphosis (any type) * posttraumatic scoliosis * neuromuscular scoliosis exclusion criteria: * previous incisions over the operative site * history of keloid formation * allergy to tape * does not consent/assent to participate in the study * previous or active spinal infection * dural tear * hemophiliac * two stage procedure * unable to follow standard antibiotic protocols
study of oral weekly gs-1720 and gs-4182 compared with biktarvy in people with hiv-1 who have not been treated

Conditions: HIV-1-infection

Summary: the goal of this clinical study is to learn more about the experimental drugs gs-1720 (an oral, long-acting integrase strand transfer inhibitor (insti)) and gs-4182 (a prodrug of lenacapavir (len)); to compare the combination of gs-1720 and gs-4182 with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (b/f/taf) (biktarvy), to see if the combination of gs-1720 and gs-4182 is safe and if it works for treating human immunodeficiency virus type 1 (hiv-1) infection in treatment-naive people with hiv-1 (pwh). this study has two phases: phase 2 and phase 3. the primary objectives of this study are: phase 2: to evaluate the efficacy of oral weekly gs-1720 coadministered with gs-4182 versus continuing biktarvy (bvy) in treatment-naive pwh at week 24. phase 3: to evaluate the efficacy of oral weekly gs-1720/gs-4182 fixed-dose combination (fdc) tablet regimen versus continuing bvy in treatment-naive pwh at week 48.


Eligibility criteria:
key inclusion criteria: * hiv-1 rna ≥ 500 copies/ml at screening. * antiretroviral (arv) treatment-naive, except the use of oral pre-exposure prophylaxis (prep) or postexposure prophylaxis (pep) with emtricitabine/tenofovir disoproxil fumarate (ftc/tdf) or f/taf, up to 1 month prior to screening. key exclusion criteria: * prior use of any long acting parenteral antiretrovirals (arvs) such as monoclonal antibodies, broadly neutralizing antibodies targeting hiv-1, len, injectable cabotegravir (including oral cabotegravir lead-in), and/or injectable rilpivirine. * documented resistance to the integrase strand-transfer inhibitor class, specifically, resistance-associated mutations e92g/q, g118r, f121y, y143c/h/r, s147g, q148h/k/r, n155h/s, or r263k in the integrase gene. * any of the following laboratory values at screening: 1. cd4 cell count \< 200 cells/mm3 at screening. 2. estimated glomerular filtrations arate \< 60 ml/min according to the modification of diet in renal disease formula. 3. hepatic transaminases (aspartate aminotransferase and alanine aminotransferase) \> 1.5 × upper limit of normal (uln). 4. direct bilirubin \> 1.5 × uln. 5. platelets count \< 50,000 cells/mm3. 6. hemoglobin \< 8.0 g/dl. * active or occult hepatitis b virus infection. * active hepatitis c virus infection. note: other protocol defined inclusion/exclusion criteria may apply.
comparative trial of micafungin versus fluconazole for treating esophageal candidiasis

Conditions: Candidiasis, Oral

Summary: to determine the efficacy and safety of iv micafungin versus iv fluconazole in the treatment of patients with esophageal candidiasis


Eligibility criteria:
inclusion criteria: * diagnosis of esophageal candidiasis confirmed by endoscopy * negative pregnancy test in females of childbearing potential exclusion criteria: * pregnant or nursing * evidence of liver disease * presence of another active opportunistic fungal infection and/or receiving acute systemic therapy for an opportunistic fungal infection * concomitant esophagitis caused by herpes simplex virus or cytomegalovirus * receipt of an oral or topical antifungal agent within 48 hours or a systemic agent within 72 hours of first dose of study drug * non-responsive to therapy in any prior systemic antifungal clinical trail * history of \> 2 episodes of esophageal candidiasis requiring systemic antifungal therapy * history of anaphylaxis attributed to azole compounds or echinocandin class of antifungals

Keywords: micafungin esophageal candidiasis fluconazole
seroconversion in covid-19 recovered population

Conditions: Covid19

Summary: this study investigate the kinetics of igg responses to both n and s proteins in the subjects who suffered from covid 19 and then had recovered.

coronaviruses (covs) are enveloped, single positive-strand rna viruses belonging to the large subfamily coronavirinae, which can infect mammals and several other animals.the continued spread of coronavirus disease 2019 (covid-19) has prompted widespread concern around the world, and the world health organization (who), on 11 march 2020, declared covid-19 a pandemic. studies on severe acute respiratory syndrome (sars) and middle east respiratory syndrome (mers) showed that virus-specific antibodies were detectable in 80-100% of patients at 2 weeks after symptom onset. currently, the antibody responses against sars-cov-2 remain poorly understood and the clinical utility of serological testing is unclear little is known about the kinetics, tissue distribution, cross-reactivity and neutralization antibody response in covid-19 patients . the seropositivity rate of both igm and igg responses after onset and recovery of disease, and in the context of both n protein and s protein has not been clarified. the kinetics of antibody responses in critical cases or icu patients has not been reported, and no studies have suggested whether antibody response is associated with disease prognosis

Eligibility criteria:
inclusion criteria: subjects recovered from covid 19 confirmed on pcr or clinically exclusion criteria: subjects who have not been confirmed suffering from covid 19 by pcr or clinically
oropharyngeal administration of colostrum

Conditions: Health Behavior

Summary: infections are the main causes of morbidity and mortality in very low birth weight infants. use of mother's own breast milk in feeding these babies is associated with a decreased risk of acquiring nosocomial infection. this protective effect is assigned to a plurality of immune components in human milk. however, clinical instability of the preterm newborn in the first days of life results in delayed initiation of enteral nutrition. thus, alternative methods for colostrum administration have been investigated, such as oropharyngeal administration with evidence that would be safe and feasible to perform in children admitted to the nicu in the first hours of life. objective: to evaluate the immune stimulatory effect of oropharyngeal administration of colostrum in the incidence of sepsis in very low birth weight preterm infants.

background: infections are the main causes of morbidity and mortality in very low birth weight infants. use of mother's own breast milk in feeding these babies is associated with a decreased risk of acquiring nosocomial infection. this protective effect is assigned to a plurality of immune components in human milk. however, clinical instability of the preterm newborn in the first days of life results in delayed initiation of enteral nutrition. thus, alternative methods for colostrum administration have been investigated, such as oropharyngeal administration with evidence that would be safe and feasible to perform in children admitted to the nicu in the first hours of life. objective: to evaluate the immune stimulatory effect of oropharyngeal administration of colostrum in the incidence of sepsis in very low birth weight preterm infants. methods: this was a prospective, randomized and blind study that included infants less than 34 weeks gestational age and birth weight less than 1,500 g, from 15 july 2013 to 15 july 2015. the babies were divided initially into two groups for oropharyngeal administration or not of mother's own milk: group 1 - underwent oropharyngeal administration of mother's own milk of and group 2 - underwent oropharyngeal administration of sterile water, considered an inert substance. newborns who were drawn to the group 1 and it was not possible to obtain sufficient mother's own milk volume constituted a third group called group 3 that receive oropharyngeal administration of donor breast milk. oropharyngeal administration were initiated within the first 48-72 hours of life and maintained for 48 hours. before the oropharyngeal administration, 24 hours after and 14 days after, samples of blood and urine were collected from the newborns to iga and lactoferrin dosage.

Eligibility criteria:
inclusion criteria: * birth weight \< 1500 g and gestational age \< 34 weeks exclusion criteria: * congenital anomalies * gastrointestinal disorders * maternal history of substance abuse or positive maternal hiv status.

Keywords: colostrum